SeV986A
Our group utilizes an replication-defective Sendai virus (SeV) as TB vaccine vector, and constructed SeV85AB and SeV986A vaccine. SeV986A expressed a fusion of acute- and latency-stage Mtb antigens (4 antigens). In murine models, it serves as a potent BCG-booster, significantly reducing bacterial burden in both active and latent infection challenges.
Read MoreAd5Ag85A*
Ad5Ag85A is a human adenovirus serotype 5-vectored vaccine expressing Antigen 85A (Ag85A). This vaccine is delivered by the inhaled aerosol route.
Read MoreChAdOx1.5Ag/MVA.5Ag
ChAdOx1.5Ag is a recombinant, replication deficient chimpanzee adenovirus, expressing the four antigens of the mycobacterium Esx-5a system (PPE15, PE8, EsxI, EsxJ), along with Ag85A. In mice, ChAdOx1.5Ag improved the efficacy of BCG in the lung and spleen, and a further boost with MVA.5Ag further improved efficacy in the spleen. ChAdOx1.5Ag/MVA.5Ag was also promising in non-human…
Read MoreTB/FLU-05E
TB/FLU-05E is a mucosal TB vaccine candidate based on recombinant attenuated influenza vector (Flu/THSP) co-expressing truncated NS1 protein NS1(1–124) and a full-length TB10.4 and HspX proteins of M.tb within an NS1 protein open reading frame. Vaccine formulation: Liquid nasal spray.
Read MoreTB/FLU-04L*
Based on the attenuated influenza strain Flu NS106/ESAT-6_Ag85A expressing mycobacterial antigens Esat-6 and Ag85A.
Read More